Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP415 Efficacy Classroom Study in Children with ADHD
NCT03292952Phase 3Completed
- Sponsor
- Zevra Therapeutics
- Start
- Dec 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of serdexmethylphenidate + dexmethylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Zevra Therapeutics. Started Dec 2017; status: completed.
02
Drugs
serdexmethylphenidate + dexmethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03292952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292952.